Brookstone Capital Management Makes New Investment in United Therapeutics Corporation (NASDAQ:UTHR)

Brookstone Capital Management acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,798 shares of the biotechnology company's stock, valued at approximately $1,479,000.

Other large investors have also recently added to or reduced their stakes in the company. Cerity Partners LLC grew its stake in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after acquiring an additional 2,702 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after acquiring an additional 376 shares during the last quarter. Korea Investment CORP grew its stake in United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after acquiring an additional 2,300 shares during the last quarter. Nepsis Inc. grew its stake in United Therapeutics by 6.7% in the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock valued at $18,057,000 after acquiring an additional 3,653 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $1,899,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on UTHR. Cantor Fitzgerald began coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research note on Monday, May 5th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, Bank of America decreased their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $386.15.

United Therapeutics Trading Up 1.8%

NASDAQ:UTHR traded up $5.26 during trading hours on Tuesday, hitting $295.65. The stock had a trading volume of 37,893 shares, compared to its average volume of 444,926. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The business has a 50 day simple moving average of $301.08 and a two-hundred day simple moving average of $321.54. The company has a market cap of $13.34 billion, a PE ratio of 11.81, a price-to-earnings-growth ratio of 6.45 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter last year, the company earned $6.17 earnings per share. United Therapeutics's revenue for the quarter was up 17.2% on a year-over-year basis. Research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the sale, the director owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $285.70, for a total transaction of $3,142,700.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at approximately $10,508,331.70. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 76,681 shares of company stock valued at $22,813,739. Corporate insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.